STAR - Strand’s Target Analysis Report, provides in-depth scientific assessment of drug targets relevant to the pharmaceutical and biotechnology industry. These reports are developed from an exhaustive analysis of scientific literature survey and public databases. This includes recent data on disease association, pathways, polymorphisms, genetic alterations, expression, biomarkers, and sequence characteristics such as protein domains, orthologs and promoters.

STAR offers scientists an actionable and easy-to-read report that contains several supplementary data tables for further analysis and exploration, thus leading to insights for developing better drug candidates. These reports are presented in an intuitive format complemented with relevant graphical representations and summary tables as supporting evidence.

Whether you are a discovery biologist, medicinal chemist, clinical researcher, licensing manager, project manager, portfolio manager, or external research manager, STAR helps you quickly get to the most current knowledge of targets and diseases in this fast moving field. If you are in a large pharmaceutical or a small biotechnology company, STAR saves valuable time and money, and helps you in your drug discovery and development strategies.

STAR is written by experienced PhD scientists for research scientists. Cross-functional experts in biology, bioinformatics, genomics and proteomics are the core of the STAR team.

List of Report Overviews

STRAND TARGET ANALYSIS CUSTOMIZED REPORTS

Strand produces STAR reports on a customized basis as well. Strand can create reports based on your companies individual specifications and targets.

If you would like to inquire about this service and to request pricing please contact John Talalas at Starsales@strandls.com or 617-905-2800.